Paris Roach

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. ncbi A 75% insulin lispro/25% NPL mixture provides a longer duration of insulin activity compared with insulin lispro alone in patients with Type 1 diabetes
    P Roach
    Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Diabet Med 20:946-52. 2003
  2. ncbi Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide
    - Roach
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Clin Ther 23:1732-44. 2001
  3. ncbi New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations
    Paris Roach
    Division of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Clin Pharmacokinet 47:595-610. 2008
  4. ncbi A critical dialogue: communicating with type 2 diabetes patients about cardiovascular risk
    Paris Roach
    Department of Medicine, Division of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Vasc Health Risk Manag 1:301-7. 2005
  5. ncbi Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes
    P Roach
    Indiana University School of Medicine and Eli Lilly and Company, Indianapolis, IN 46202, USA
    Diabet Med 23:743-9. 2006
  6. ncbi Better systems, not guidelines, for glucose monitoring
    Paris Roach
    Division of Endocrinology and Metabolism Indiana University School of Medicine 545 Barnhill Drive, Emerson Hall Room 421 Indianapolis, IN 46202, USA
    BMJ 329:E332. 2004
  7. ncbi Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus
    Paris Roach
    Department of Medicine, Indiana University School of Medicine, 545 Barnhill Drive, EH 421, Indianapolis, IN 46202, USA
    Clin Ther 26:502-10. 2004
  8. ncbi Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus
    P Roach
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Diabetes Obes Metab 5:311-6. 2003
  9. ncbi Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures
    Paris Roach
    Department of Medicine, Indiana University School of Medicine, Indianapolis 46202, USA
    Clin Pharmacokinet 41:1043-57. 2002
  10. ncbi Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting
    Nancy M Yoon
    Division of Endocrinology and Metabolism, School of Medicine, Indiana University, Indianapolis, Indiana 46202, USA
    Clin Ther 31:1511-23. 2009

Collaborators

Detail Information

Publications13

  1. ncbi A 75% insulin lispro/25% NPL mixture provides a longer duration of insulin activity compared with insulin lispro alone in patients with Type 1 diabetes
    P Roach
    Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Diabet Med 20:946-52. 2003
    ....
  2. ncbi Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide
    - Roach
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Clin Ther 23:1732-44. 2001
    ..Humalog Mix25 (Mix25) is a premixed insulin mixture of 25% insulin lispro and 75% neutral protamine lispro...
  3. ncbi New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations
    Paris Roach
    Division of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Clin Pharmacokinet 47:595-610. 2008
    ..For technical and practical reasons, other alternative routes have generally not met with clinical success...
  4. ncbi A critical dialogue: communicating with type 2 diabetes patients about cardiovascular risk
    Paris Roach
    Department of Medicine, Division of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Vasc Health Risk Manag 1:301-7. 2005
    ..Research is needed to find the best methods for communicating risk in daily clinical practice...
  5. ncbi Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes
    P Roach
    Indiana University School of Medicine and Eli Lilly and Company, Indianapolis, IN 46202, USA
    Diabet Med 23:743-9. 2006
    ....
  6. ncbi Better systems, not guidelines, for glucose monitoring
    Paris Roach
    Division of Endocrinology and Metabolism Indiana University School of Medicine 545 Barnhill Drive, Emerson Hall Room 421 Indianapolis, IN 46202, USA
    BMJ 329:E332. 2004
  7. ncbi Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus
    Paris Roach
    Department of Medicine, Indiana University School of Medicine, 545 Barnhill Drive, EH 421, Indianapolis, IN 46202, USA
    Clin Ther 26:502-10. 2004
    ..When used in a similar fashion, premixed, fixed-ratio insulin preparations containing LP and NPL (an LP-based intermediate-acting insulin) may provide the basis for an optimized basal-bolus insulin regimen...
  8. ncbi Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus
    P Roach
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Diabetes Obes Metab 5:311-6. 2003
    ....
  9. ncbi Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures
    Paris Roach
    Department of Medicine, Indiana University School of Medicine, Indianapolis 46202, USA
    Clin Pharmacokinet 41:1043-57. 2002
    ..The combined rapid and prolonged insulin activity provided by insulin lispro mixtures has been defined both in healthy subjects without diabetes and in patients with diabetes...
  10. ncbi Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting
    Nancy M Yoon
    Division of Endocrinology and Metabolism, School of Medicine, Indiana University, Indianapolis, Indiana 46202, USA
    Clin Ther 31:1511-23. 2009
    ..Limited published data exist on the off-label use of exenatide in conjunction with insulin in the treatment of T2DM...
  11. ncbi Dose accuracy testing of the humalog/ humulin insulin pen device
    M J Roe
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46268, USA
    Diabetes Technol Ther 3:623-9. 2001
    ..Also 92% (n = 59) of patients interviewed felt that the stop mechanism for the final dose was clear. Extensive testing in the development of a prefilled insulin delivery device demonstrates an accurate and reliable medical device...
  12. ncbi Investing time in health: do socioeconomically disadvantaged patients spend more or less extra time on diabetes self-care?
    Susan L Ettner
    Division of General Internal Medicine and Health Services Research, Department of Medicine, University of California Los Angeles, 911 Broxton Plaza, Los Angeles, CA 90095, USA
    Health Econ 18:645-63. 2009
    ..Research on self-care for chronic disease has not examined time requirements. Translating Research into Action for Diabetes (TRIAD), a multi-site study of managed care patients with diabetes, is among the first to assess self-care time...
  13. ncbi Good diabetes care: more than cheap meds
    Ronald T Ackermann
    Med Care 42:99-101. 2004